Equities Analysts Issue Forecasts for argenex Q4 Earnings

argenex SE (NASDAQ:ARGX) – Equities research analysts at William Blair upped their Q4 2026 earnings per share estimates for shares of argenex in a research report issued to clients and investors on Thursday, October 30th. William Blair analyst M. Minter now anticipates that the company will post earnings of $10.12 per share for the quarter, up from their previous forecast of $9.53. The consensus estimate for argenex’s current full-year earnings is $3.13 per share.

Several other research firms also recently weighed in on ARGX. TD Cowen lifted their target price on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research report on Friday. Royal Bank Of Canada lifted their target price on argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a research report on Friday. JPMorgan Chase & Co. lifted their target price on argenex from $775.00 to $830.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Piper Sandler lifted their target price on argenex from $750.00 to $820.00 and gave the company an “overweight” rating in a research report on Tuesday, August 26th. Finally, Truist Financial boosted their price objective on argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $851.70.

argenex Price Performance

NASDAQ ARGX opened at $818.50 on Monday. The company has a market cap of $50.40 billion, a P/E ratio of 35.14, a P/E/G ratio of 0.94 and a beta of 0.45. The stock has a 50-day moving average of $769.14 and a two-hundred day moving average of $654.84. argenex has a 1-year low of $510.05 and a 1-year high of $855.46.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. argenex had a return on equity of 29.78% and a net margin of 41.58%.

Hedge Funds Weigh In On argenex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. WPG Advisers LLC acquired a new position in argenex in the first quarter valued at approximately $37,000. Brooklyn Investment Group boosted its holdings in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 38 shares in the last quarter. MAI Capital Management boosted its holdings in argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after purchasing an additional 78 shares in the last quarter. Mather Group LLC. acquired a new position in argenex in the third quarter valued at approximately $50,000. Finally, Banque Transatlantique SA acquired a new position in argenex in the first quarter valued at approximately $62,000. 60.32% of the stock is owned by institutional investors and hedge funds.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.